## Package 'UnplanSimon'

January 20, 2025

Type Package

Title Methods for Managing Enrollment Deviation in Simon's Two-Stage Design

Version 0.1.0

Maintainer Yunhe Liu <yunhe.liu@tamu.edu>

**Description** Methods for managing under- and over-enrollment in Simon's Two-Stage Design are offered by providing adaptive threshold adjustments and sample size recalibration. It also includes post-inference analysis tools to support clinical trial design and evaluation. The package is designed to enhance flexibility and accuracy in trial design, ensuring better outcomes in oncology and other clinical studies. Yunhe Liu, Haitao Pan (2024). Submitted.

License GPL (>= 3)

Encoding UTF-8

RoxygenNote 7.3.2

Imports stats

**Depends** R (>= 3.5.0)

Suggests knitr, rmarkdown, clinfun (>= 3.0.0)

VignetteBuilder knitr

NeedsCompilation no

Author Yunhe Liu [aut, cre], Haitao Pan [aut]

**Repository** CRAN

Date/Publication 2024-10-25 09:10:06 UTC

### Contents

ATSS_Design_Stage1	2
ATSS_Design_Stage2	3
ATS_Design	4
SimonAnalysis	5
	- 7

Index

ATSS\_Design\_Stage1

#### Description

ATSS\_Design\_Stage1() provides an Adaptive Threshold and Sample Size Simon Design (ATSS Simon) method for Simon's two stage design in oncology trials when the realized sample sizes in the first stage is different from the planned sample sizes in the first stage. When under-enrollment or over-enrollment occurs at the first stage, we identify the design parameters (r1\*, r\*, n\*) based on the actual sample size n1\* ar the first stage to satisfy the type I error rate and power. In addition, the ATSS Simon design also satisfies the other criteria as in the originally planned design, such as minimizing the average sample size under the null hypothesis H0.

#### Usage

ATSS\_Design\_Stage1(p0, p1, n1\_star, alpha, beta)

#### Arguments

p0	Unacceptable efficacy rate
p1	Desirable efficacy rate
n1_star	The actual number of patients in stage 1
alpha	Original Type-I error rate
beta	Original Type-II error rate

#### Value

a data frame includes the Adaptive Threshold and Sample Simon Design interim analysis' adjusted first stage threshold r1\*, second stage threshold r\*, actual number of patients in the first stage n1\*, new design planned two stages' patients n\*, attained Type-I error rate and Power, Average sample size under null hypothesis EN(p0) and Probability of early termination under null hypothesis PET(p0).

#### References

Yunhe Liu, & Haitao Pan. (2024). Clinical Trial Design Methods for Managing Under- and Over-Enrollment in Simon's Two-Stage Design, Submitted.

#### Examples

```
# Adaptive Threshold and Sample Size Simon Design interim analysis case 1
ATSS_Design_Stage1(0.05, 0.20, 20, 0.10, 0.10)
# r1* r* n1* n* Type I Power EN(p0) PET(p0)
# ATSS_Design_Stage1 1 3 20 35 0.08 0.901 23.962 0.736
# Adaptive Threshold and Sample Size Simon Design interim analysis case 2
```

```
# r1* r* n1* n* Type I Power EN(p0) PET(p0)
# ATSS_Design_Stage1 2 4 18 26 0.099 0.904 20.13 0.734
```

ATSS\_Design\_Stage2 Adaptive Threshold and Sample Size Simon Design Two Stages

#### Description

ATSS\_Design\_Stage2() provides an Adaptive Threshold and Sample Size Simon Design (ATSS Simon) method for Simon's two stage design in oncology trials when the realized sample sizes in the second stage is different from the planned sample sizes in the second stage from interim analysis new design. Further adjustment of the threshold at the second stage is needed. So, we update again the second stage threshold r\* to satisfy the type I error rate given the interim analysis design first stage threshold r1\* and actual two stages sample sizes (n1\*, n\*\*).

#### Usage

ATSS\_Design\_Stage2(p0, p1, r1\_star, n1\_star, n\_double\_star, alpha)

#### Arguments

p0	Unacceptable efficacy rate
p1	Desirable efficacy rate
r1_star	Interim analysis design threshold in stage 1
n1_star	The actual number of patients in stage 1
n_double_star	The actual total number of patients in stages 1 and 2
alpha	Original Type-I error rate

#### Value

a data frame includes the Adaptive Threshold and Sample Size Simon Design interim analysis design adjusted first stage threshold r1\*, Adaptive Threshold and Sample Simon Design stage 2 new design adjusted second stage threshold r\*, actual number of patients in the first stage n1\*, actual total number of patients in stages 1 and 2 n\*\*, attained Type-I error and Power, Average sample size under null hypothesis EN(p0) and Probability of early termination under null hypothesis PET(p0).

#### References

Yunhe Liu, & Haitao Pan. (2024). Clinical Trial Design Methods for Managing Under- and Over-Enrollment in Simon's Two-Stage Design, Submitted.

#### Examples

ATS\_Design Adaptive Threshold Simon Design

#### Description

ATS\_Design() provides an Adaptive Threshold Simon Design (ATS Simon) method for Simon's two-stage design in oncology trials when the realized sample sizes in the first stage and/or the second stage(s) are different from the planned sample sizes in the first stage and/or the second stage(s). The Proposed ATS Simon design aims to adhere to sample sizes of the original design, to that end, this design updates the original thresholds of (r1, r) in the first and/or the second stages to satisfy the type I error rate as the original planned design (note: power will decrease if the realized sample size is smaller than the original one).

#### Usage

ATS\_Design(n1, n, n1\_star, n\_star, r1, r, p0, p1, alpha)

#### Arguments

n1	The planned number of patients in stage 1
n	The planned number of patients in stages 1 and 2
n1_star	The actual number of patients in stage 1
n_star	The actual total number of patients in stages 1 and 2
r1	Original design threshold in stage 1
r	Original design threshold in stage 2
p0	Unacceptable efficacy rate
p1	Desirable efficacy rate
alpha	Original type-I error rate

#### Value

a data frame includes the Adaptive Threshold Simon Design (ATS Simon) first stage threshold r1\*, second stage threshold r\*, actual first stage patients n1\*, actual total sample sizes of the two stages patients n\*, updated type I error constraint alpha(n\*), attained type-I error and Power, Average sample size under null hypothesis EN(p0) and Probability of early termination under null hypothesis PET(p0).

4

#### SimonAnalysis

#### References

Yunhe Liu, & Haitao Pan. (2024). Clinical Trial Design Methods for Managing Under- and Over-Enrollment in Simon's Two-Stage Design, Submitted.

#### Examples

SimonAnalysis

Post-Trial Inference for ATS and ATSS Simon Designs

#### Description

SimonAnalysis() can be used to calculate the Uniformly minimum-variance unbiased estimator (UMVUE), Confidence Intervals (Clopper-Pearson, Jung exact, and Mid-p) and p-Value given the design parameters obtained from the Adaptive Threshold Simon Design (ATS Simon) design and Adaptive Threshold and Sample Simon Design (ATSS Simon) design using ATS\_Design(), ATSS\_Design\_Stage1() and ATSS\_Design\_Stage2().

#### Usage

SimonAnalysis(m, s, n1, n2, r1, r, alpha, quantile, CI\_option, p0)

#### Arguments

m	Stopping stage of the ATS or ATSS Simon Designs
S	The number of responses observed in total
n1	The actual number of patients in stage 1
n2	The actual total number of patients in stages 1 and 2
r1	The design threshold in stage 1
r	The design threshold in stage 2
alpha	Type-I error rate
quantile	Two tails probability of the confidence interval
CI_option	The type of confidence interval, the character can be typed by "CP", "Jung" or "MIDp" corresponding to the Clopper-Pearson, Jung exact, or Midp confidence intervals
p0	Unacceptable efficacy rate

#### Value

a data frame includes the Uniformly minimum-variance unbiased estimator (UMVUE), chosen Confidence Interval and *p*-Value

#### References

Jung, S. H., & Kim, K. M. (2004). On the estimation of the binomial probability in multistage clinical trials. Statistics in medicine, 23(6), 881-896, doi:10.1002/sim.1653.

Clopper, C. J., & Pearson, E. S. (1934). *The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika*, 26(4),404-413, doi:10.2307/2331986.

Porcher, R., & Desseaux, K. (2012). What inference for two-stage phase II trials?. BMC medical research methodology, 12, 1-13, doi:10.1186/1471228812117.

Jung, S. H., Owzar, K., George, S. L., & Lee, T. (2006). *P-value calculation for multistage phase II cancer clinical trials. Journal of Biopharmaceutical Statistics*, *16*(6), 765-775, doi:10.1080/10543400600825645.

#### Examples

```
# Post-Trial inference for ATS or ATSS Simon Designs case 1
SimonAnalysis(2,7,13,30,3,12,0.05,c(0.025,0.975),"MIDp",0.40)
# Analysis Plan
                       UMVUE CI(lower) CI(upper) p_Val
#
# Post-Trial Inference 0.322
                                 0.108
                                           0.538 0.831
# Post-Trial inference for ATS or ATSS Simon Designs case 2
SimonAnalysis(2,16,11,28,2,13,0.077,c(0.025,0.975),"Jung",0.25)
# Analysis Plan
                      UMVUE CI(lower) CI(upper) p_Val
#
# Post-Trial Inference 0.429
                                 0.257
                                           0.568 0.019
```

# Index

ATS\_Design,4 ATSS\_Design\_Stage1,2 ATSS\_Design\_Stage2,3

SimonAnalysis, 5